What is the formula to calculate FIB-4 (Fibrosis-4) score?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

FIB-4 Score Calculation

The FIB-4 score is calculated using the formula: [Age (years) × AST (IU/L)] / [Platelet count (×10⁹/L) × √ALT (IU/L)] 1, 2, 3.

Required Laboratory Values

To calculate FIB-4, you need exactly four values 2:

  • Age in years
  • AST (aspartate aminotransferase) in IU/L or U/L
  • ALT (alanine aminotransferase) in IU/L or U/L
  • Platelet count in ×10⁹/L (or divide by 1000 if reported as ×10³/μL)

Step-by-Step Calculation

  1. Multiply the patient's age by their AST value 3
  2. Take the square root of the ALT value 1, 3
  3. Multiply the platelet count by the square root of ALT 3
  4. Divide the result from step 1 by the result from step 3 1, 2

Interpretation Thresholds

For most adult populations 2, 4:

  • FIB-4 <1.3: Low probability of advanced fibrosis (negative predictive value ~90-95%) 2, 4
  • FIB-4 1.3-2.67: Indeterminate range requiring additional testing with elastography or Enhanced Liver Fibrosis testing 2
  • FIB-4 >2.67: High probability of advanced fibrosis (positive predictive value ~65%) 2, 4

Age-adjusted threshold for elderly patients 2:

  • FIB-4 <2.0 for patients ≥65 years old to account for age-related increases in the score 2

Clinical Performance Characteristics

The FIB-4 index demonstrates an AUROC of 0.77-0.86 for detecting advanced fibrosis across different liver disease populations 2, 3, 4. The test performs best at ruling out advanced fibrosis rather than confirming it, with negative predictive values exceeding 90% 2, 4.

Important Caveats

Age significantly affects FIB-4 values, causing higher false-positive rates in elderly patients and potential false-negatives in younger patients 2. The score naturally increases with age independent of fibrosis progression 2.

In NAFLD populations specifically, diabetes and metabolic syndrome may reduce diagnostic accuracy 2. When using FIB-4 in cystic fibrosis-related liver disease, insufficient validation data exists for optimal thresholds 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.